Opus Genetics (R3X1) Price & Analysis

3 Followers

R3X1 Stock Chart & Stats

€3.26

-€0.10(-3.07%)

At close: Jul 31 4:00 PM EDT

€3.26

-€0.10(-3.07%)

Day’s Range― - ―

52-Week Range€1.00 - €4.84

Previous CloseN/A

Volume0.00

Average Volume (3M)3.00

Market Cap

€271.37M

Enterprise Value€405.18

Total Cash (Recent Filing)€88.81M

Total Debt (Recent Filing)€34.93M

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Nov 17, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding83,195,820

10 Day Avg. Volume0

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)81.49

Price to Sales (P/S)88.10

P/FCF Ratio-35.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€9.51

Price Target Upside191.82% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-0.9

Revenue Forecast (FY)€11.45M

Bulls Say, Bears Say

Bulls Say

Broad Gene-therapy PipelineA portfolio spanning five inherited retinal disease programs diversifies clinical risk and creates multiple opportunities for data, regulatory progress and eventual commercialization over the next several years.

Rare-disease PositioningFirst-mover positioning in specialized retinal diseases and access to rare-disease incentives could support differentiated development, faster regulatory pathways and stronger competitive protection if clinical results are successful.

Pipeline Funding VisibilityStated funding visibility through 2029 would allow Opus to pursue several programs and reach planned clinical milestones without immediate operational disruption, potentially preserving the value of upcoming data readouts.

Bears Say

Severe Operating LossesExtremely deep operating and net losses indicate that current revenue is insufficient to support the business, leaving future progress dependent on successful development, major cost control or additional financing.

Negative Equity And DebtNegative equity combined with new debt weakens financial flexibility and may constrain financing options, especially while the company remains loss-making and requires substantial investment in clinical development.

Persistent Cash BurnSustained and worsening cash consumption means Opus relies on external funding to maintain operations, creating dilution or liquidity risk if clinical spending continues before products generate meaningful revenue.

Opus Genetics News

Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed

Longeveron (LGVN) announced that the company has appointed Nirav Jhaveri to the company’s executive leadership team in the...

9d ago

IRD

LGVN

Opus Genetics price target lowered to $9 from $10 at RBC Capital

RBC Capital lowered the firm’s price target on Opus Genetics (IRD) to $9 from $10 and keeps an...

22d ago

IRD

Opus Genetics files $300M mixed securities shelf

06:23 EDT Opus Genetics (IRD) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

22d ago

IRD

Opus Genetics reports Q2 EPS (14c), consensus (16c)

Reports Q2 revenue $755,000, consensus $2.57M. “With a focus on execution, we are rapidly advancing five gene therapy...

23d ago

IRD

Opus Genetics enrolls last patient in OPGx-LCA5 trial

Opus Genetics (IRD) announced that the last patient has been enrolled in its registrational Phase 3 clinical trial...

26d ago

IRD

Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained

Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on Opus Genetics. The associated price target remains...

13h ago

IRD

Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from...

19d ago

IRD

Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from...

22d ago

IRD

Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028

TD Cowen analyst Ritu Baral has maintained their bullish stance on IRD stock, giving a Buy rating yesterday....

22d ago

IRD

IRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Opus Genetics, Inc. (IRD) is scheduled to report 2nd quarter earnings on 08/07/2026. Regarding Q2 estimates, Wall Street...

24d ago

IRD

Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Opus Genetics. The associated price target remains...

25d ago

IRD

Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock

Insiders have been trading these 5 stocks: (($IRD)), (($CYTK)), (($ACI)), (($WFRD)) and (($PAYS)). Here is a breakdown of...

28d ago

ACI

IRD

CarMax, MPLX, Opus, BJ’s, CoStar Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($KMX) ), ( ($MPLX) ), ( ($IRD) ), ( ($BJ)...

28d ago

IRD

Opus Genetics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Opus Genetics (IRD) with a Buy rating without a price target The company’s...

1M ago

IRD

R3X1 FAQ

What was Opus Genetics’s price range in the past 12 months?

Opus Genetics lowest stock price was €1.00 and its highest was €4.84 in the past 12 months.

What is Opus Genetics’s market cap?

Opus Genetics’s market cap is €271.37M.

When is Opus Genetics’s upcoming earnings report date?

Opus Genetics’s upcoming earnings report date is Nov 17, 2026 which is in 80 days.

How were Opus Genetics’s earnings last quarter?

Opus Genetics released its earnings results on Aug 06, 2026. The company reported -€0.12 earnings per share for the quarter, beating the consensus estimate of -€0.135 by €0.015.

Is Opus Genetics overvalued?

According to Wall Street analysts Opus Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opus Genetics pay dividends?

Opus Genetics does not currently pay dividends.

What is Opus Genetics’s EPS estimate?

Opus Genetics’s EPS estimate is -0.12.

How many shares outstanding does Opus Genetics have?

Opus Genetics has 83,195,820 shares outstanding.

What happened to Opus Genetics’s price movement after its last earnings report?

Opus Genetics reported an EPS of -€0.12 in its last earnings report, beating expectations of -€0.135. Following the earnings report the stock price went down -2.516%.

Which hedge fund is a major shareholder of Opus Genetics?

Currently, no hedge funds are holding shares in DE:R3X1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Opus Genetics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

140.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opus Genetics

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Opus Genetics (R3X1) Earnings & Revenues

Historic Earnings Reports

R3X1 Stock 12 Month Forecast

Average Price Target

€9.51

▲(191.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"€14","-1":"-€1","2.75":"€2.75","6.5":"€6.5","10.25":"€10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.73376416,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.513492881666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€9.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.86688208,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.75,6.5,10.25,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.16,3.973366473846154,4.7867329476923075,5.600099421538461,6.413465895384615,7.226832369230769,8.040198843076922,8.853565316923078,9.66693179076923,10.480298264615385,11.293664738461539,12.107031212307692,12.920397686153846,{"y":13.73376416,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.16,3.648730221666667,4.1374604433333335,4.626190665,5.114920886666667,5.603651108333333,6.09238133,6.581111551666666,7.069841773333334,7.558571994999999,8.047302216666665,8.536032438333333,9.02476266,{"y":9.513492881666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.16,3.4451447753846156,3.730289550769231,4.015434326153846,4.300579101538462,4.585723876923077,4.870868652307692,5.156013427692308,5.441158203076923,5.726302978461538,6.011447753846154,6.296592529230769,6.581737304615384,{"y":6.86688208,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.916,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.022,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.958,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.706,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.656,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.695,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.055,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >